Thus, we focused our efforts on improving CAR-M-mediated phagocytosis of melanoma cells by engineering the CSPG4-targeting chimeric antigen receptor to contain the intracellular FcRγ phagocytic signaling domain and combining the CSPG4-targeting CAR-Ms with CD47 blocking antibodies. Here, CSPG4 is linked to melanoma.